Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Should You Buy the Dip in Eli Lilly Stock Right Now?
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly dropped by as much as 8% and ended the day down around 6%. Year-to-date, share prices are down about 1.4%.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Has Eli Lilly Stock Peaked?
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.
Eli Lilly Faces ‘Death Cross’ Selloff: This is the Stock's Next Target Price...
Shares of Eli Lilly were already in an intermediate-term decline before the announcement. The stock has dropped 25% from its 2024 highs as investors have been unimpressed with Eli Lilly’s drug pipeline and management.
Leerink keeps Eli Lilly stock outperform on revenue growth
Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently valued at $672.
1d
on MSN
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.
1d
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Boston College
2h
Boston College receives $10 million grant from Lilly Endowment
Boston College has received a $10 million grant from Lilly Endowment Inc. to support an Institute for Advanced Jesuit Studies ...
4d
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
1d
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
Eli Lilly & Co. (LLY) is rebounding from Friday's sales disappointment, finding support at $722 and set for another uptrend.
7d
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Glide Magazine
12h
Lilly Hiatt Takes Ambitious Approach to Alt-rock and Americana Sounds on ‘Forever’ (ALBUM REVIEW)
Coming four years after her last record, Forever is Lilly Hiatt’s strongest blend yet of alt-rock guitars with Americana ...
10h
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
FiercePharma
21h
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
WEHT Evansville on MSN
17h
Lilly King to speak at OCTC’s 8th Annual Trailblazer Dinner
The Owensboro Community and Technical College announces Lilly King as the special guest speaker for its 8th Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
United States
Zepbound
Wegovy
Omvoh
Novo Nordisk
Feedback